Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03585673
Other study ID # DAUHIRB-18-041
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2018
Est. completion date March 30, 2021

Study information

Verified date July 2018
Source Dong-A University Hospital
Contact Sung Yong Oh, MD
Phone +82512402808
Email drosy@dau.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed. In this study, The investigators wanted to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly administration chemotherapy for the participants with inoperable or metastatic esophageal squamous cell carcinoma.


Description:

Few results directly study the combination of docetaxel and oxaliplatin in the squamous cell cancer of the esophagus, but some studies have shown that it is safe to In the phase II study for the patients with gastroesophageal junction adenocarcinoma, a prior study reported the efficacy and safety of the combination therapy of docetaxel 80mg/m2 and oxaliplatin 100mg/m2 every 3 weeks schedule. Entire response rate was 34% and median survival duration was 11.6 months. Over grades 3 anemia and neutropenia were found in 17%, respectively, and non-hematological toxicities were mostly mild to moderate. In this study, a five-day preventive granulocyte colony-stimulating factor (G-CSF) was used to reduce hematology toxicity.

Meanwhile, there was the phase I/II studies of added capecitabine to docetaxel and oxaliplatin with divided schedule d1 and d8 every 3weeks for reducing toxicities. The subjects who participated in this study had at least one previous history of chemotherapy, but overall response rates were 43% and median values for the entire duration of survival were 9.8months. However, the side effects were significant, with 30 % of patients seeing diarrhea of Grade 3 or higher and 17 % seeing infection of Grade 3 or higher (SAE) reported at 37 %.

Looking at the reasons and background for this, the effects of docetaxel on esophageal squamous cell cancer patients are already known, and weekly divided administration has also demonstrated a reasonable level of effectiveness and safety. In studies conducted on gastric and esophageal adenocarcinoma, the combination of docetaxel and oxaliplatin also showed reasonable levels of effects and side effects.

In this study, The investigators wanted to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly administration chemotherapy for the participants with inoperable or metastatic esophageal squamous cell carcinoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date March 30, 2021
Est. primary completion date March 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. A patient whose squamous cell cancer of the esophagus or esophago-gastric junction has been confirmed by biopsy or cytology.

2. A patient who is not subject to local treatment such as surgical excision or concurrent definitive chemoradiotherapy.

3. Metastatic or relapsed esophageal cancer patients who planned first line palliative treatment.

4. Patients' age over 18

5. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-2

6. Patient has measurable lesions with RECIST v1.1

7. Patients with appropriate organ functions, such as the following, within seven days prior to the start of a clinical trial

- Proper bone marrow function (ANC = 1500/uL, Platelets = 100,000/uL and Hb 8/microliter(uL))

- Proper kidney function (serum creatinine = 1.5 mg/L, 24-hour urine test or creatinine clearance = 60 ml/min based on Cockcroft-Gault formula)

- Appropriate liver function (bilirubin = 1.5 mg/dL, transaminases aspartate transaminase (AST or SGOT) and alanine transaminase (AST or SGOT) = 2.5 times normal upper limit)

8. Patients with at least three months of an expected life.

9. Signing written consent from patients or their legal guardians and understanding the right to withdraw consent at any time without disadvantage.

Exclusion Criteria:

1. In the case that the following treatment has been received in the past for the local stage treatment more than 6 months from the end of the treatment, enrolment is allowed.

- Neoadjuvant chemotherapy

- Concurrent or sequential chemoradiotherapy

- Adjuvant chemotherapy

- Adjuvant concurrent or sequential chemoradiotherapy

- Definitive concurrent or sequential chemoradiotherapy

2. Patients with a history of administration of docetaxel, paclitaxel, or oxaliplatin at any time in the past.

3. Patients who have been treated for other active cancers other than esophageal cancer less than five years (but cured kin basal cell cancer or cured cervical carcinoma in situ are excluded).

4. The clinically confirmed esophagus obstruction, gastrointestinal bleeding, or perforation (except if the symptoms are sufficiently controlled through proper procedures such as stents).

5. Patients with significant, uncontrolled cardiovascular disease, infection, or infectious fever.

6. Patients with uncontrolled brain metastasis.

7. In the case of major surgery within the first two weeks of clinical trial treatment, the patient must recover sufficiently from the effects of this surgery.

8. Patients with pregnancy, breast feeding, or future plans.

9. Because of uncontrolled diabetes or diabetic neuropathy, patients who have any subjective symptoms regardless of their degree

10. Patients who have taken antihistamine or steroid within four weeks of clinical trial treatment

11. In combination with the state of Docetaxel-PM, patients who are not permitted to take combined medication (patients with severe renal dysfunction, para-platin, platinum compound, patients who have hypersensitivity to mannitol, etc.)

12. Patients with hypersensitivity history of Polysorbate 80

13. A patient who has hypersensitivity history to Docetaxel-PM or oxaliplatin or any drug containing platinum.

14. Patients with peripheral sensory neuropathy with functional impairment (may aggravate peripheral neuropathy) prior to clinical trial

15. Other cases

- Have experienced an infection or other serious medical problems that could cause damage to a patient's functions, making it difficult for the patient to receive treatment in a research plan.

- Mental, neurological, or dementia that can prevent a person from understanding and submitting a written statement and consent form

- Patients who are certain to be out of the clinical trial or who cannot be monitored regularly for the following reasons: For example, psychological, social, family or geographical reasons, or conditions that make it difficult to observe or comply with appropriate clinical trial plans.

- Uncontrolled hepatitis and chronic liver disease

- Other patients who are judged unfit for clinical trials by their physicians and researchers

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Docetaxel-PM
Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
Oxaliplatin
Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression

Locations

Country Name City State
Korea, Republic of Dong-A University Hospital Busan

Sponsors (1)

Lead Sponsor Collaborator
Sung Yong Oh

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rate complete response + partial response by RECIST up to 6 months
Secondary Progression free survival progression or death up to 12 months
Secondary Overall survival death event up to 12 months
Secondary Adverse event Hypersensitivity or any side effects by NCI-Common Terminology Criteria for Adverse Events (CTCAE) v4.03 up tp 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Withdrawn NCT00005030 - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Not yet recruiting NCT05981170 - Rurality Adapted Physical Activity Sport Health
Not yet recruiting NCT03058809 - Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood Phase 1/Phase 2
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1
Terminated NCT00918645 - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis N/A
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00795678 - Chemotherapeutic Agents in Brain/Breast N/A
Completed NCT00557102 - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung Phase 2
Recruiting NCT00398437 - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer N/A